GlobeNewsWire · IFRX · November 6, 2026

InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan

Get the app for more

Explore stock news, insights and company research.